Research led by Wardah Shahzadi

Writers: Aimen Shahid, Fatima Shamim, Aamna Asim

‍‍Overview of Genetic Mutations in Pediatric Cancer:

Genetic mutations play a crucial role in the development of pediatric cancers, as they can lead to uncontrolled cell growth and tumor formation. Some common genetic mutations in pediatric cancers are:

 1.        TP53:

The TP53 gene provides instructions for making a protein called tumor protein p53 (or p53). This protein acts as a tumor suppressor, which means that it regulates cell division by keeping cells from growing and dividing (proliferating) too fast or in an uncontrolled way. Now you can imagine if this gene was to mutate what damage it could cause. Mutations in the TP53 gene are commonly seen in various pediatric cancers, including Li-Fraumeni syndrome, a condition that predisposes individuals to a wide range of cancers, including sarcomas, breast cancer, brain tumors, and leukemia. TP53 mutations are also linked to pediatric cancers like rhabdomyosarcoma (muscle cancer) and neuroblastoma (cancer of the nerve tissue).

 Most TP53 mutations change single amino acids in the p53 protein, which leads to the production of an altered version of the protein that cannot control cell proliferation and is unable to trigger apoptosis in cells with mutated or damaged DNA. As a result, DNA damage can accumulate in cells. Such cells may continue to divide in an uncontrolled way, leading to tumor growth.

 2.        EGFR (Epidermal Growth Factor Receptor):

EGFR is a type of receptor found in cells that is involved in normal growth and is closely related to other receptors in the same family. It plays a role in various processes related to cancer, such as cell proliferation, apoptosis, angiogenesis, and metastasis. Increased expression of EGFR is often seen in different types of tumors, and it is being studied as a potential target for anticancer therapy.

 3.        ALK (Anaplastic Lymphoma Kinase):

Mutations in this gene are associated with cancers like neuroblastoma and anaplastic large cell lymphoma. ALK mutations lead to abnormal cell signaling that drives tumor growth.

 Inherited vs. Acquired Genetic Mutations:

If a parent carries a gene mutation in their egg or sperm, it can pass to their child. These hereditary or inherited mutations are in almost every cell of the person's body throughout their life. If a harmful change (aka mutation) is present in a gene that is important in protecting against cancer, then the pathogenic variant stops the gene from working properly, resulting in an increased risk for that person to develop cancer over their lifetime.

 There are over 50 known hereditary cancer syndromes, some of which are better-known, such as Hereditary Breast and Ovarian Cancer (HBOC) syndrome and Lynch syndrome, and others that are lesser-known, including familial adenomatous polyposis (FAP) syndrome and von Hippel-Lindau (VHL) syndrome. Regardless, each hereditary cancer syndrome is caused by pathogenic variants in different genes, and the risk for cancer in each syndrome varies. Inherited gene mutations are not the main cause of most cancers.

 An acquired gene mutation is not inherited from a parent. Instead, it develops at some point during a person's life. Acquired mutations occur in one cell, and then are passed on to any new cells that come from that cell. This mutation cannot be passed on to a person's children, because it doesn’t affect their sperm or egg cells. This type of mutation is also called a sporadic mutation or a somatic mutation.

 Acquired mutations can happen for different reasons. Sometimes they happen when a cell’s DNA is damaged, such as after being exposed to radiation or certain chemicals. But often these mutations occur randomly, without having an outside cause. For example, during the complex process when a cell divides to make 2 new cells, the cell must make another copy of all of its DNA, and sometimes mistakes (mutations) occur while this is happening. Every time a cell divides is another chance for gene mutations to occur. The number of mutations in our cells can build up over time, which is why we have a higher risk of cancer as we get older. Acquired gene mutations are a much more common cause of cancer than inherited mutations.

 Children with inherited mutations may be more predisposed to developing specific types of cancer early in life. Early detection through genetic testing, surveillance, and preventive measures can improve the outcome for these children.Most pediatric cancers result from acquired mutations that happen after birth. These mutations are typically random, though environmental factors may play a role in increasing the risk.

 Genetic Mutations in Specific Pediatric Cancers:‍

Pediatric cancers often arise due to genetic mutations. These mutations disrupt normal cell growth and differentiation, leading to uncontrolled proliferation. Genomic sequencing studies have highlighted that pediatric cancers typically have few somatic mutations but a higher prevalence of germline alterations in cancer predisposition genes. The contribution of germline variants in pediatric tumors has been estimated between 8 and 12%. Below is a detailed breakdown of genetic mutations associated with specific pediatric cancers:

 1.        Leukemia (Acute Lymphoblastic Leukemia - ALL & Acute Myeloid Leukemia - AML): 

Leukemia is considered a genetic disease because it is caused by mutations in genes that affect the behavior of cells, especially white blood cells . These mutations can be the result of errors in cell production or external influences like chemical exposure or radiation.

>        Acute Lymphoblastic Leukemia (ALL):

­        ETV6-RUNX1 (TEL-AML1) Fusion: ( Mutation) One of the most common genetic changes in pediatric ALL (25% of cases). Results from the translocation t(12;21)(p13;q22). Disrupts normal hematopoietic differentiation and increases proliferation.

­        MLL Rearrangements (KMT2A mutations): Found in infant ALL (children under 1 year). t(4;11)(q21;q23) fuses the MLL gene with AF4, resulting in an aggressive leukemia subtype.

­        BCR-ABL1 (Philadelphia Chromosome-like ALL):  t(9;22)(q34;q11) translocation. Leads to the production of a constitutively active tyrosine kinase that drives uncontrolled cell division. Targeted therapy: Tyrosine Kinase Inhibitors (TKIs) like Imatinib.

>        Acute Myeloid Leukemia (AML):

­        RUNX1-RUNX1T1 (AML1-ETO ) MUTATION:  t(8;21)(q22;q22) translocation. Blocks differentiation of myeloid precursors.

­        CBFB-MYH11( MUTATION ): Inv(16)(p13q22) inversion. Impairs normal hematopoietic differentiation.

­        FLT3-ITD Mutation: Internal tandem duplication in FLT3. Leads to hyperactive tyrosine kinase signaling and poor prognosis.

­        NPM1 Mutation: Mutations in exon 12 of NPM1. Associated with a better prognosis when present without FLT3 mutations.

 2.        Neuroblastoma:

Neuroblastoma (NB) originates from neural crest cells and affects the nervous sympathetic system. NB exhibits unique features, such as early age of onset, high frequency of metastatic disease at diagnosis in patients over 1 year of age, and the tendency for spontaneous regression of tumors in infants. In high-risk cases, the survival rate is only 50%.It is a kind of  neural crest-derived tumor affecting infants and young children.

>        MYCN Amplification: present in 20-30% of high-risk neuroblastomas. MYCN encodes a transcription factor that promotes cell cycle progression and prevents apoptosis. Correlates with aggressive disease and poor prognosis.

>         ALK Mutations: Activating mutations in the ALK gene (Anaplastic Lymphoma Kinase).ALK inhibitors (e.g., Crizotinib) are used as targeted therapy.

>         Chromosome 1p and 11q Deletions: Loss of tumor suppressor genes, leading to genomic instability.‍

3.        Medulloblastoma (Brain Tumor):

Medulloblastomas grow most often in the central part of the cerebellum and less frequently in the outer parts of the cerebellum. Medulloblastoma accounts for 15 to 20 percent of all pediatric brain tumors and occur most commonly in children between the ages of 3 and 8 but can be seen in children and adults of any age. There are about 350 cases of medulloblastoma diagnosed each year in the United States. It is known as  highly malignant embryonal tumor of the cerebellum. The outcomes for children with medulloblastoma have improved dramatically over the past several decades. Doctors historically have classified medulloblastoma as either standard or high risk based on biopsy results. In recent years, however, studies have shown that what we call medulloblastoma could actually be several different diseases. In fact, medulloblastoma can be divided into four molecular subtypes based on specific types of gene mutations within the tumor. Each subtype has a distinct survival rate, ranging from 20 to 90 percent.

>        WNT Subgroup: Mutations in CTNNB1 (β-catenin). Good prognosis, minimal metastasis.

>        SHH Subgroup (Sonic Hedgehog Pathway Mutations): PTCH1, SMO, SUFU mutations disrupt SHH signaling. Leads to abnormal proliferation of cerebellar granule neuron precursors.

 4.        Nephroblastoma aka WILMS TUMOUR :

Wilms tumor is a rare kidney cancer that mainly affects children. Also known as nephroblastoma, it's the most common cancer of the kidneys in children. Wilms tumor most often affects children ages 3 to 4. It becomes much less common after age 5, but it can affect older children and even adults.

­        WT1 Mutations: WT1 is a tumor suppressor gene critical for kidney development.Mutations result in improper differentiation of kidney progenitor cells.

­        WAGR Syndrome (WT1 Deletion): Wilms tumor, Aniridia, Genitourinary anomalies, and Retardation.

­        Loss of Heterozygosity (LOH) at 11p15: Results in IGF2 overexpression, promoting growth

­        TP53 Mutations: Associated with anaplastic (aggressive) Wilms tumor.

 5.        Retinoblastoma:

Retinoblastoma (RB) is a pediatric malignancy of the neural retina, commonly initiated by biallelic inactivation of RB1  and affecting one (unilateral) or both eyes (bilateral). The median age at diagnosis is 12 months in bilateral tumors and 24 months in unilateral ones. Patient survival is >95% in high-income countries but <30% globally  The first studies on RB unveiled the importance of genetics in cancer; indeed, the “two-hit hypothesis” formulated by Knudson  on RB1 has been paradigmatic for the understanding of tumor-suppressor genes and the study of familial cancers.

>        RB1 Gene Mutations: RB1 is a tumor suppressor gene on chromosome 13q14.Loss of both alleles leads to unchecked retinal cell proliferation. RB is generally described as retinoblastoma predisposition syndrome since germline RB1 mutations lead to a high risk of second primary malignancie. Interestingly, RB onset is reported in 13q deletion syndrome, caused by deletion of part of the long arm of chromosome 13, where RB1 is located. Patients with this syndrome show a very wide phenotypic spectrum depending on the size and the location of the deletion.

>        Hereditary vs. Sporadic: Hereditary (Germline) affects both eyes, increased risk of secondary cancers. Sporadic (Somatic) is unilateral (one eye), no increased secondary cancer risk. Sporadic RB is always unilateral. Biallelic loss of RB1 is found in 98% of cases, whereas 2% show MYCN amplification. A significant proportion of sporadic RB exhibits somatic mosaicism for RB1 mutations. Hereditary RB encompasses about 40% of all cases with most having bilateral tumors, 15% unilateral, and 5% trilateral (associated with midline brain tumor) 

 6.        Ewing sarcoma:

Ewing Sarcoma is a type of cancer that begins as a growth of cells in the bones and the soft tissue around the bones. Ewing (Yoo-ing) sarcoma mostly happens in children and young adults, although it can happen at any age. Ewing sarcoma most often begins in the leg bones and in the pelvis, but it can happen in any bone. Less often, it starts in the soft tissues of the chest, abdomen, arms or other locations.

>        EWSR1-FLI1 Fusion:  t(11;22)(q24;q12) translocation. Creates an oncogenic transcription factor that promotes cell growth.

>        CD99 Overexpression: Helps in the diagnosis of Ewing sarcoma.

 However, Genetic mutations play a crucial role in pediatric cancers, influencing prognosis, treatment options, and therapeutic targets. Advances in genomic sequencing and targeted therapies are improving survival rates and personalized treatment approaches for children with cancer. Moreover, Genetic mutations play a fundamental role in the development of pediatric cancers by disrupting normal cellular functions such as proliferation, differentiation, and apoptosis. Lets look into how these mutations drive oncogenesis in specific pediatric cancers:

‍

1.        Philadelphia Chromosome in Leukemia:

It’s Mutation Mechanism involves, The Philadelphia chromosome (Ph) arises due to a reciprocal translocation which is ,:t(9;22)(q34;q11)t(9;22)(q34;q11)t(9;22)(q34;q11), This translocation fuses the BCR (Breakpoint Cluster Region) gene on chromosome 22 with the ABL1 (Abelson Murine Leukemia Viral Oncogene Homolog 1) gene on chromosome 9. The fusion leads to the production of BCR-ABL1, an abnormal, constitutively active tyrosine kinase.

It’s effect on cellular function includes , Constitutive Activation of Tyrosine Kinase: The BCR-ABL1 fusion protein continuously activates downstream signaling pathways such as:

>        RAS/MAPK Pathway → Promotes proliferation.

>        PI3K/AKT Pathway → Inhibits apoptosis

>        JAK/STAT Pathway → Induces uncontrolled cell growth

Leads to excessive production of immature white blood cells (blast cells), crowding out normal hematopoietic cells.

It’s clinical impact includes, Philadelphia chromosome-positive (Ph+) Acute Lymphoblastic Leukemia (ALL) is more common in older children and has a historically poor prognosis. Targeted therapy with tyrosine kinase inhibitors (TKIs) like Imatinib (Gleevec) or Dasatinib has dramatically improved survival rates.

 2.        MYCN Amplification in Neuroblastoma:

It’s Mutation Mechanism involves, MYCN is an oncogene located on chromosome 2p24, encoding the N-Myc transcription factor, which regulates cell cycle progression and differentiation. MYCN amplification results in the overproduction of N-Myc, which: Drives rapid proliferation., Suppresses apoptosis, induces genomic instability, making cells more aggressive.

It’s effect on cellular Functions involve around N-Myc activates multiple pro-tumorigenic pathways: Upregulation of CDKs (Cyclin-Dependent Kinases): Forces the cell cycle forward., Inhibition of p53 Pathway: Blocks apoptosis., Induction of Angiogenesis: Promotes tumor vascularization. Neuroblastoma cells with MYCN amplification exhibit poor differentiation, making them highly aggressive and prone to metastasis.

3.        RB1 Mutation in Retinoblastoma:

It’s Mutation Mechanism Includes, Biallelic mutations in the RB1 gene on chromosome 13q14 lead to retinoblastoma. The RB1 protein is a tumor suppressor that regulates the G1/S checkpoint of the cell cycle. It’s Effect on cellular Function includes Loss of RB1 leads to uncontrolled cell division because it: fails to inhibit E2F transcription factors, allows unchecked cell cycle progression. Its clinical Impact revolves arounds, Hereditary Retinoblastoma: Germline mutations in RB1 predispose to bilateral tumors and secondary cancers (e.g., osteosarcoma). Sporadic Retinoblastoma: Usually unilateral and results from somatic RB1 mutations. Therapeutic Approaches: Gene Therapy: Restoring RB1 function is being explored. Chemo-reduction and Focal Therapy for localized tumors. Genetic mutations in pediatric cancers disrupt normal regulatory pathways, leading to uncontrolled cell division, loss of differentiation, and metastasis. Advances in molecular diagnostics and targeted therapies (e.g., tyrosine kinase inhibitors, MYCN inhibitors, and transcription factor-targeting drugs) are improving outcomes for pediatric cancer patients.

‍‍

 Role of Tumor Suppressor Genes and Oncogenes in Childhood Cancer:

Pediatric cancers arise from genetic and epigenetic changes that disrupt the normal balance of cell proliferation and apoptosis. Two major classes of genes are involved in this process:

Tumor Suppressor Genes (TSGs) → Act as brakes to prevent uncontrolled cell growth

Oncogenes → Act as accelerators that promote excessive cell division when mutated or overactivated.

1.        Tumor Suppressor Genes (TSGs):

Tumor suppressor genes (TSGs) inhibit cell proliferation, promote apoptosis, and maintain DNA stability. Mutations in these genes lead to uncontrolled cell division and cancer formation. Unlike oncogenes, which require only a single mutated copy to drive cancer, TSGs usually follow the two-hit hypothesis (both alleles must be inactivated for cancer to develop). So far, many studies have identified numerous TSGs and illustrated their functions in various types of tumors or normal samples. Furthermore, accumulating evidence has shown that non-coding RNAs can act as TSGs to prevent the tumorigenesis processes.

Key Tumors include:

­   RB1 (Retinoblastoma Protein) - Retinoblastoma and Osteosarcoma

­   TP53 (Tumor Protein p53) - Multiple Childhood Cancers

­   WT1 (Wilms Tumor 1) - Wilms Tumor (Nephroblastoma)

­       NF1 (Neurofibromin 1) - Neurofibromatosis and Optic Gliomas

­       APC (Adenomatous Polyposis Coli) - Medulloblastoma

2.       Oncogenes:

Oncogenes are mutated or overactivated proto-oncogenes that drive cancer by promoting cell proliferation, inhibiting apoptosis, or enabling uncontrolled growth. Unlike tumor suppressor genes, only one copy of an oncogene needs to be mutated to drive cancer (dominant gain-of-function mutation). The first fusion oncogenes were discovered in leukemia and other hematologic cancers. In the 1980s, a fusion between 3′ of the ABL1 gene in chromosome 9 and 5′ of the BCR gene in chromosome 22 (BCR/ABL) was identified in a subset of patients with leukemia.In 2001, a tyrosine kinase inhibitor (TKI) targeting BCR/ABL, imatinib mesylate, was approved for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. This represented one of the first targeted therapies used for patients with CML. Treatment with imatinib  mesylate led to significant improvements in length of remission. The success of this agent showed the promise of targeting oncogenic fusions in the treatment of cancer. The progress in sequencing technology has enabled the exploration of additional fusion oncogenes in other cancer types.

Key Oncogenes include:

­       MYCN - Neuroblastoma and Medulloblastoma

­       ALK (Anaplastic Lymphoma Kinase) - Neuroblastoma and Lymphom

­       BCR-ABL1 (Philadelphia Chromosome) - Leukemia

­       RAS (KRAS/NRAS) - Leukemia and Rhabdomyosarcoma

­       PAX3-FOXO1 - Rhabdomyosarcoma

Environmental Factors and their interactions with Genetic Mutations in Pediatric Cancer:

While childhood cancers are primarily driven by genetic mutations, environmental factors can contribute by triggering or accelerating these mutations. Unlike adult cancers, where factors like smoking and prolonged toxin exposure play a major role, pediatric cancers are less commonly associated with environmental carcinogens. However, certain environmental influences can still increase mutation rates, disrupt DNA repair mechanisms, or interfere with normal cellular development in children such as:

1.        Ionizing Radiation (X-rays, Gamma Rays, CT Scans): It directly damages DNA by breaking double-strand DNA. Increases the risk of chromosomal translocations (e.g., BCR-ABL1 fusion in leukemia).associated pediatric cancers are Leukemia (ALL, AML) and Brain tumors (Medulloblastoma, Gliomas). Children exposed to radiation from atomic bomb explosions in Hiroshima and Nagasaki had higher leukemia rates due to radiation-induced DNA damage.

2.        Ultraviolet (UV) Radiation: creates pyrimidine dimers in DNA, leading to TP53 mutations. Melanoma (Rare but increasing in children)however, Sunscreen and limited sun exposure can reduce UV-induced DNA damage.

3.        Chemical Exposure (Pesticides, Heavy Metals, Air Pollutants): Some chemicals are direct mutagens (e.g., benzene, found in gasoline, damages DNA). Endocrine-disrupting chemicals (EDCs) mimic hormones and interfere with cell growth regulation. Associated Cancers involve , Leukemia (ALL, AML) and ,Neuroblastoma, Studies suggest a link between maternal pesticide exposure and increased leukemia risk in children.

4.        Infections (Viruses & Bacteria): Some viruses insert their genetic material into host DNA, leading to mutations. Chronic infections trigger inflammation, increasing DNA damage. Associated Pediatric cancer involves Epstein-Barr Virus (EBV) Burkitt Lymphoma, Human Papillomavirus (HPV) → Pediatric Sarcomas, EBV infection in immunocompromised children increases the risk of Burkitt lymphoma by causing MYC translocations.

 By Limiting radiation exposure (CT scans, X-rays), which can Reduces DNA damage risk, reducing exposure to pesticides and pollutants which can Lowers leukemia and neuroblastoma risk, Vaccination against cancer-causing viruses (HPV, EBV) which can Prevents viral-associated cancers, and in advance Folic acid supplementation during pregnancy can lead towards Reducing risk of neural tube defects and epigenetic dysregulation.

 However, Genetic mutations are the primary drivers of pediatric cancers, but environmental factors can influence their onset and progression.Some environmental exposures cause direct DNA mutations (radiation, chemicals), while others affect epigenetic regulation (maternal diet, infections).Children with predisposing genetic mutations (e.g., TP53, RB1, NF1) are more vulnerable to environmental damage. Preventive measures, such as avoiding excessive radiation and reducing exposure to known carcinogens, can lower the risk of environmentally induced mutations in children..

Genetic Testing and Early Detection in Pediatric Cancer:

Genetic testing has revolutionized early detection in pediatric oncology by identifying children at higher risk of developing cancer. Several key advancements include:

1.        Next-Generation Sequencing (NGS)– NGS, massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionised genomic research. Using NGS an entire human genome can be sequenced within a single day. In contrast, the previous 'Sanger sequencing' technology, used to decipher the human genome, required over a decade to deliver the final draft. The main disadvantage of NGS in the clinical setting is putting in place the required infrastructure, such as computer capacity and storage, and also the personnel expertise required to comprehensively analyse and interpret the subsequent data. In addition, the volume of data needs to be managed skilfully to extract the clinically important information in a clear and robust interface. The actual sequencing cost of NGS is negligible.

2.        Liquid Biopsies– A liquid biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumour through a simple blood sample. Traces of the cancer’s DNA in the blood can give clues about which treatments are most likely to work for that patient.

3.        Whole-Exome Sequencing (WES) & Whole-Genome Sequencing (WGS)– All the pieces of an individual's DNA that provide instructions for making proteins, called exons, are thought to make up 1 percent of a person's genome. Together, all the exons in a genome are known as the exome, and the method of sequencing them is known as whole exome sequencing. This method allows variations in the protein-coding region of any gene to be identified, rather than in only a select few genes. Because most known mutations that cause disease occur in exons, whole exome sequencing is thought to be an efficient method to identify possible disease-causing mutations.

 However, researchers have found that DNA variations outside the exons can affect gene activity and protein production and lead to genetic disorders--variations that whole exome sequencing would miss. Another method, called whole genome sequencing, determines the order of all the nucleotides in an individual's DNA and can determine variations in any part of the genome. Although, because not all genetic changes affect health, it is difficult to know whether identified variants are involved in the condition of interest.

 In addition to being used in the clinic, whole exome and whole genome sequencing are valuable methods for researchers. Continued study of exome and genome sequences can help determine whether new genetic variations are associated with health conditions, which will aid disease diagnosis in the future.

Multi-Gene Panel Testing– Focused sequencing of multiple cancer-associated genes helps detect hereditary cancer syndromes, such as Li-Fraumeni syndrome and familial retinoblastoma.

 Identifying At-Risk Children most commonly children with a family history of cancer or inherited genetic mutations are more susceptible to developing pediatric cancers. Genetic screening programs help identify such individuals, enabling preventive measures such as increased surveillance and lifestyle modifications.

Genetic Testing in Treatment Decisions and Prognosis:

Genetic profiling plays a crucial role in tailoring treatment strategies, as different genetic mutations respond to different therapies:

1.        Risk Stratification: Classifies patients based on genetic markers to determine treatment intensity. It involves tailoring elements of the cancer screening programme, such as test modality, screening interval or eligibility criteria, based on personal risk determined using individual level characteristics. Such an approach ensures that screening is targeted to those with the highest cancer risk whilst minimising harm to people of lower risk.

2.        Targeted Therapies: This is a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. It is the foundation of precision medicine.

3.        Reduced Toxicity: Identifying low-risk patients can prevent overtreatment and long-term side effects.

4.        Monitoring Relapse: Minimal residual disease (MRD) detection through genetic tests helps assess treatment response and relapse risks.

Future Directions in Targeted Therapies and Personalized Medicine:

Understanding Genetic Mutations for Personalized Treatments:

The identification of oncogenic drivers in pediatric cancers is revolutionizing treatment approaches:

1.        Gene Therapy: Techniques like CRISPR and viral vector-based delivery aim to correct mutations at the DNA level.

2.        Targeted Drugs: Small-molecule inhibitors (e.g., BRAF inhibitors for gliomas) and monoclonal antibodies (e.g., GD2-targeted therapy for neuroblastoma) selectively attack cancer cells.

3.        Immunotherapy: it's a type of cancer treatment that harnesses the body’s immune system to recognize and destroy cancer cells. Recent breakthroughs in immunotherapy have provided new treatment options for pediatric cancers (like CAR-T Cell Therapy and Immune Checkpoint Inhibitors), especially for those resistant to conventional therapies like chemotherapy and radiation.

 ‍

Challenges and Promises of Targeted Therapies:

>        Challenges:

1.        Tumor Heterogeneity: Cancer is a dynamic disease. During the course of disease, cancers generally become more heterogeneous. As a result of this heterogeneity, the bulk tumour might include a diverse collection of cells harbouring distinct molecular signatures with differential levels of sensitivity to treatment. This heterogeneity might result in a non-uniform distribution of genetically distinct tumour-cell subpopulations across and within disease sites (spatial heterogeneity) or temporal variations in the molecular makeup of cancer cells (temporal heterogeneity). Heterogeneity provides the fuel for resistance; therefore, an accurate assessment of tumour heterogeneity is essential for the development of effective therapies. Multiregion sequencing, single-cell sequencing, analysis of autopsy samples, and longitudinal analysis of liquid biopsy samples are all emerging technologies with considerable potential to dissect the complex clonal architecture of cancers.

2.        Limited Drug Availability: Many targeted therapies for adult cancers are not yet approved for pediatric use.

 3.        High Costs: Personalized medicine is expensive and advanced therapies like CAR-T and gene editing become inaccessible in low-income regions.

 4.        Long-Term Effects: Since their bodies are still developing, the impact of early targeted treatments on childhood development remains uncertain.

>       Promises:

1.        Higher Efficacy: Treatments tailored to a tumor’s genetic profile improve response rates and reduce toxicity.

 2.        Precision Drug Development: Ongoing research aims to expand the range of genetic targets in pediatric cancers.

 3.        Combination Therapies: Using targeted drugs with chemotherapy or immunotherapy enhances effectiveness

 4.        Advances in Biomarker Discovery: Identifying novel genetic markers improves early diagnosis and treatment customization.

Targeted therapies hold great promise in treating pediatric cancers, but there is still a lot to learn. Much of the research on targeted therapy has been in adult patients, and doctors need to find out more about how the drugs work in children. For many types of cancers, targeted drugs are not yet available. Cancer cells are complex, and finding the right target is challenging.

 Scientists are hopeful that targeted therapy and precision medicine approaches will provide long term cures with fewer side effects for many pediatric cancer patients.  

‍